Seeking Alpha

InVivo, Ligand, Biostar extend gains in afternoon trading

  • Several of today's healthcare winners are extending their gains meaningfully as the sessions wears on.
  • InVivo (NVIV +56%) has skyrocketed since updating investors on its degradable polymer scaffold program earlier in the day.
  • Ligand Pharmaceuticals (LGND +8.5%) has more than doubled its early gains on the strength of an upgrade at Cantor, where analyst Irina Rivkind is now "more comfortable with the growth prospects for the business based primarily on management's higher guidance on material sales and milestones."
  • Biostar Pharmaceuticals (BSPM +16.5%) is up double-digits after posting modest premarket gains, bringing the two-day rally to ~92%.
Comments (2)
  • sophocles
    , contributor
    Comments (210) | Send Message
     
    Cantor analyst raised LGND from SELL to HOLD. I wonder what would happen if said BUY.
    15 Nov 2013, 02:57 PM Reply Like
  • rx7no1
    , contributor
    Comments (6) | Send Message
     
    INVIVO
    If the FDA protocol still requires a three month delay between each patient treated it won't matter how many centers available to use the scaffoldit will be close to a year and a half before enough patients are treated and evealuated before we could get a Phase II going.
    Our best hope is that the first patients show remarkable,
    irefutable improvement above base line and force the FDA to allow an expedited program.
    Also to get the hydrogel back on track to get into a trial uneder way before the end of next year.
    Under Reynolds the company NEVER met promised deadlines and the minute this new management misses one of theirs there will be a collective blast of disgust from us long holding long abused shareholders.
    15 Nov 2013, 04:41 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector